Mimedx Group Stock Price To Earning
| MDXG Stock | USD 9.22 0.16 1.77% |
MiMedx Group fundamentals help investors to digest information that contributes to MiMedx's financial success or failures. It also enables traders to predict the movement of MiMedx Stock. The fundamental analysis module provides a way to measure MiMedx's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to MiMedx stock.
MiMedx | Price To Earning |
MiMedx Group Company Price To Earning Analysis
MiMedx's Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Current MiMedx Price To Earning | 23.73 X |
Most of MiMedx's fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, MiMedx Group is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
MiMedx Price To Earning Driver Correlations
Understanding the fundamental principles of building solid financial models for MiMedx is extremely important. It helps to project a fair market value of MiMedx Stock properly, considering its historical fundamentals such as Price To Earning. Since MiMedx's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of MiMedx's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of MiMedx's interrelated accounts and indicators.
Click cells to compare fundamentals
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
| Competition |
MiMedx Retained Earnings
Retained Earnings |
|
Based on the latest financial disclosure, MiMedx Group has a Price To Earning of 23.73 times. This is 8.17% lower than that of the Biotechnology sector and notably higher than that of the Health Care industry. The price to earning for all United States stocks is 17.37% higher than that of the company.
MiMedx Price To Earning Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses MiMedx's direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of MiMedx could also be used in its relative valuation, which is a method of valuing MiMedx by comparing valuation metrics of similar companies.MiMedx is currently under evaluation in price to earning category among its peers.
MiMedx Current Valuation Drivers
We derive many important indicators used in calculating different scores of MiMedx from analyzing MiMedx's financial statements. These drivers represent accounts that assess MiMedx's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of MiMedx's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 810.7M | 983.0M | 666.5M | 313.9M | 1.0B | 1.1B | |
| Enterprise Value | 807.2M | 934.9M | 627.6M | 296.5M | 987.8M | 1.0B |
MiMedx ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, MiMedx's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to MiMedx's managers, analysts, and investors.Environmental | Governance | Social |
MiMedx Fundamentals
| Return On Equity | 0.62 | ||||
| Return On Asset | 0.18 | ||||
| Profit Margin | 0.26 % | ||||
| Operating Margin | 0.14 % | ||||
| Current Valuation | 1.26 B | ||||
| Shares Outstanding | 146.95 M | ||||
| Shares Owned By Insiders | 2.45 % | ||||
| Shares Owned By Institutions | 68.15 % | ||||
| Number Of Shares Shorted | 4 M | ||||
| Price To Earning | 23.73 X | ||||
| Price To Book | 7.36 X | ||||
| Price To Sales | 3.88 X | ||||
| Revenue | 321.48 M | ||||
| Gross Profit | 219.53 M | ||||
| EBITDA | 40.52 M | ||||
| Net Income | 67.44 M | ||||
| Cash And Equivalents | 72.5 M | ||||
| Cash Per Share | 0.64 X | ||||
| Total Debt | 48.1 M | ||||
| Debt To Equity | 0.69 % | ||||
| Current Ratio | 3.53 X | ||||
| Book Value Per Share | 1.23 X | ||||
| Cash Flow From Operations | 26.77 M | ||||
| Short Ratio | 8.91 X | ||||
| Earnings Per Share | 0.57 X | ||||
| Price To Earnings To Growth | 2.97 X | ||||
| Target Price | 13.0 | ||||
| Number Of Employees | 895 | ||||
| Beta | 1.94 | ||||
| Market Capitalization | 1.33 B | ||||
| Total Asset | 239.05 M | ||||
| Retained Earnings | (133.68 M) | ||||
| Working Capital | 118.25 M | ||||
| Current Asset | 96.31 M | ||||
| Current Liabilities | 26.78 M | ||||
| Net Asset | 239.05 M |
About MiMedx Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze MiMedx Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MiMedx using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MiMedx Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether MiMedx Group is a strong investment it is important to analyze MiMedx's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact MiMedx's future performance. For an informed investment choice regarding MiMedx Stock, refer to the following important reports:Check out MiMedx Piotroski F Score and MiMedx Altman Z Score analysis. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MiMedx. If investors know MiMedx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MiMedx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.1) | Earnings Share 0.57 | Revenue Per Share 2.447 | Quarterly Revenue Growth 0.029 | Return On Assets 0.1838 |
The market value of MiMedx Group is measured differently than its book value, which is the value of MiMedx that is recorded on the company's balance sheet. Investors also form their own opinion of MiMedx's value that differs from its market value or its book value, called intrinsic value, which is MiMedx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MiMedx's market value can be influenced by many factors that don't directly affect MiMedx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between MiMedx's value and its price as these two are different measures arrived at by different means. Investors typically determine if MiMedx is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MiMedx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.